Polysaccharopeptide from
- 1School of Pharmacy, Shanghai University of Traditional Chinese Medicine, No. 1200, Cailun Road, Shanghai 201203, China; Engineering Research Center of Shanghai Colleges for TCM New Drug Discovery, No. 1200, Cailun Road, Shanghai 201203, China
- 2School of Pharmacy, Shanghai University of Traditional Chinese Medicine, No. 1200, Cailun Road, Shanghai 201203, China; Engineering Research Center of Shanghai Colleges for TCM New Drug Discovery, No. 1200, Cailun Road, Shanghai 201203, China; Corresponding authors at:
- 3School of Pharmacy, Shanghai University of Traditional Chinese Medicine, No. 1200, Cailun Road, Shanghai 201203, China; Engineering Research Center of Shanghai Colleges for TCM New Drug Discovery, No. 1200, Cailun Road, Shanghai 201203, China; Biomedical Sciences and Chinese Medicine, School of Biological Sciences, Nanyang Technological University, Singapore; Corresponding authors at:
Abstract
Cancer recurrence remains a major challenge in prostate cancer (PCa), in part because quiescent cancer cells (QCCs) can survive conventional therapies and subsequently re-enter the cell cycle. Bioactive polysaccharides from food and medicinal mushrooms are increasingly investigated as nutraceutical ingredients for disease prevention and adjunctive health management. Polysaccharopeptide (PSP), a protein-bound polysaccharide derived from the mycelia of Coriolus versicolor , has a long history of oral use as an adjunctive bioactive preparation. Here, PSP inhibited QCC reactivation in LNCaP and PC-3 cells and restrained recurrent tumor growth in a quiescent PC-3 xenograft model. Mechanistically, PSP shortened the protein half-lives of Cyclin D3, CDK4, and CDK6, while proteasome inhibition attenuated their loss, supporting proteasome-dependent destabilization of the Cyclin D3–CDK4/6 axis. PSP also suppressed canonical and noncanonical NF-κB signaling, reduced nuclear accumulation of p65 and p52, and decreased NF-κB transcriptional activity, accompanied by decreased TNF-α and increased IL-10 expression. Oral PSP administration delayed recurrent tumor growth and prolonged overall survival in the xenograft model. Collectively, these findings identify QCC reactivation as a previously unrecognized cellular process responsive to PSP and provide mechanistic and preclinical support for further evaluation of this mushroom-derived bioactive preparation as an adjunctive strategy for recurrence-oriented PCa management.
BibTeX
@article{liu2026polysaccharopeptide,
title = {{Polysaccharopeptide from}},
author = {Mengfan Liu and Xueyang Sun and Jiayi Chen and Rongchen Dai and Hangui Ren and Man Yuan and Yang Li and Zhichao Xi and Hongxi Xu},
journal = {Journal of Functional Foods},
year = {2026},
month = oct,
doi = {10.1016/j.jff.2026.107557},
url = {https://doi.org/10.1016/j.jff.2026.107557},
note = {CC BY},
}
RIS
TY - JOUR
TI - Polysaccharopeptide from
AU - Mengfan Liu
AU - Xueyang Sun
AU - Jiayi Chen
AU - Rongchen Dai
AU - Hangui Ren
AU - Man Yuan
AU - Yang Li
AU - Zhichao Xi
AU - Hongxi Xu
PY - 2026
DA - 2026/10/30
JO - Journal of Functional Foods
DO - 10.1016/j.jff.2026.107557
UR - https://doi.org/10.1016/j.jff.2026.107557
AB - Cancer recurrence remains a major challenge in prostate cancer (PCa), in part because quiescent cancer cells (QCCs) can survive conventional therapies and subsequently re-enter the cell cycle. Bioactive polysaccharides from food and medicinal mushrooms are increasingly investigated as nutraceutical ingredients for disease prevention and adjunctive health management. Polysaccharopeptide (PSP), a protein-bound polysaccharide derived from the mycelia of Coriolus versicolor , has a long history of oral use as an adjunctive bioactive preparation. Here, PSP inhibited QCC reactivation in LNCaP and PC-3 cells and restrained recurrent tumor growth in a quiescent PC-3 xenograft model. Mechanistically, PSP shortened the protein half-lives of Cyclin D3, CDK4, and CDK6, while proteasome inhibition attenuated their loss, supporting proteasome-dependent destabilization of the Cyclin D3–CDK4/6 axis. PSP also suppressed canonical and noncanonical NF-κB signaling, reduced nuclear accumulation of p65 and p52, and decreased NF-κB transcriptional activity, accompanied by decreased TNF-α and increased IL-10 expression. Oral PSP administration delayed recurrent tumor growth and prolonged overall survival in the xenograft model. Collectively, these findings identify QCC reactivation as a previously unrecognized cellular process responsive to PSP and provide mechanistic and preclinical support for further evaluation of this mushroom-derived bioactive preparation as an adjunctive strategy for recurrence-oriented PCa management.
SN - 1756-4646
SN - 2214-9414
ER -